As the use of antibodies poses several practical limitations (Rihova, 1998), an alternate approach is to target a Tf–Ps conjugate to Tf receptors that are overexpressed on tumour cells (Faulk et al, 1980; Cavanaugh, 2002). Here, TF is linked to neoplasm.